Acquires the rights to DuPont Merck's antiviral agent rimantadine for prevention and treatment of influenza A. Financial terms were not disclosed. Pending FDA approval of the rimantadine NDA, which has been at FDA since November 1986, Forest will market the drug under the brandname Flumadine. The NDA stalled at FDA, despite an advisory committee approval recommendation, after a December 1989 New England Journal of Medicine article described rimatadine- resistant influenza.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth